I-Mab Partners CD47 with AbbVie in $2 Billion Deal; Raises $414 Million in Private Placement
publication date: Sep 4, 2020
Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement. Separately, AbbVie also acquired right-of-first-refusal to two other CD47 molecules, which if exercised, would each trigger a $500 million payment. And I-Mab raised $418 million in a private placement from Hillhouse and other investors to support trials of its clinical candidates. I-Mab said it chose AbbVie because of its immunoncology and clinical development expertise. It added that testing a combination therapy of the CD47 and AbbVie's Bcl-2 inhibitor is a possibility. More details....
Stock Symbols: (NSDQ: IMAB) (NYSE: ABBV)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.